Genentech Singapore To Buy Local Lonza Plant To Produce Avastin
This article was originally published in PharmAsia News
Executive Summary
Singapore's Roche subsidiary, Genentech Singapore, plans to buy Lonza Biologics Singapore's cell-culture plant by exercising an option. Roche plans to merge the facility, bought at a cost of $201 million and up to $48.5 million in milestone payments, with Genentech Singapore's separate facility. Roche expects to produce its Avastin (bevacizumab) in bulk for treating several types of cancer. The merger of facilities is to include about 230 Lonza employees to raise the work force at Genentech Singapore to 325. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.